Thomas Jaecklin, M.D., is senior vice president, clinical development and the medical lead of the pediatric cholestasis development program at Mirum Pharmaceuticals.
Thomas brings 20 years of academic and industry experience in several pediatric rare disease indications having recently served as senior medical director of the maralixibat program at Shire Pharmaceuticals, before it was acquired by Mirum Pharmaceuticals. Prior to Shire, Thomas was medical director at Novartis Pharma AG for strategic business development and several pediatric rare-disease development programs. Thomas is Swiss board-certified in pediatrics, neonatology and critical care medicine.
Thomas holds an M.D. from the University of Geneva and an M.Sc., in medical sciences from the University of Toronto.